Andrew S Huhn
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew S Huhn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07249554 · Combination Therapy for Alcohol Use DisorderJohns Hopkins University · not yet recruiting · Alcohol Use Disorder · principal investigator
- Ph2NCT05145764 · Suvorexant as an Adjunct to Buprenorphine in Persons Who Use FentanylJohns Hopkins University · completed · Suvorexant, Placebo, Opioid Use Disorder · principal investigator
- Ph2NCT04287062 · Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use DisorderJohns Hopkins University · completed · Sleep Disturbance, Opioid-use Disorder · principal investigator
- Ph2NCT03789214 · Medical Management of Sleep Disturbance During Opioid TaperingJohns Hopkins University · completed · Opioid Dependence, Opioid Withdrawal, Sleep Disturbance · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorderU01DA060708 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2024 to 2026 · $5,833,132 awarded in 2026Same name and institution; not confirmed by an ID
- Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomesR01DA059473 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2023 to 2026 · $1,148,520 awarded in 2026Same name and institution; not confirmed by an ID
- Evaluating the Role of the Orexin System in Circadian Rhythms of Sleep and Stress in Persons on Medication-Assisted Treatments for Opioid Use DisorderU01HL150835 · NHLBI · JOHNS HOPKINS UNIVERSITY · fiscal years 2019 to 2024 · $623,135 awarded in 2024Grant number is on one of their registry trials
- Evaluating Suvorexant for Sleep Disturbance in Opioid Use DisorderUH3DA048734 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2021 · $3,632,165 awarded in 2021Grant number is on one of their registry trials
- Evaluating Suvorexant for Sleep Disturbance in Opioid Use DisorderUG3DA048734 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2019 to 2020 · $1,076,067 awarded in 2020Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:49 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.Sci Transl Med · 202266 citationsRCR 7.0
- Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.Addict Biol · 202048 citationsRCR 3.8
- Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.Neuropsychopharmacology · 202129 citationsRCR 2.7
- Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.Anesthesiology · 201921 citationsRCR 1.6
- Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment.Addict Biol · 202415 citationsRCR 4.4
- Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain.Neuropsychopharmacology · 202312 citationsRCR 2.2
- Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.Drug Alcohol Depend · 202110 citationsRCR 0.9
- 7 citationsRCR 1.5
- 5 citationsRCR 2.5
- A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.Exp Clin Psychopharmacol · 20234 citationsRCR 0.7